Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Current Deferred Revenue: 2020-2022

Historic Current Deferred Revenue for Solid Biosciences (SLDB) over the last 1 years, with Mar 2022 value amounting to $6.2 million.

  • Solid Biosciences' Current Deferred Revenue fell 42.13% to $6.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $6.2 million, marking a year-over-year decrease of 42.13%. This contributed to the annual value of $8.1 million for FY2021, which is 61.00% down from last year.
  • Solid Biosciences' Current Deferred Revenue amounted to $6.2 million in Q1 2022, which was down 23.64% from $8.1 million recorded in Q4 2021.
  • Solid Biosciences' 5-year Current Deferred Revenue high stood at $20.7 million for Q4 2020, and its period low was $6.2 million during Q1 2022.
  • Its 3-year average for Current Deferred Revenue is $10.8 million, with a median of $9.5 million in 2021.
  • Data for Solid Biosciences' Current Deferred Revenue shows a maximum YoY crashed of 61.00% (in 2021) over the last 5 years.
  • Solid Biosciences' Current Deferred Revenue (Quarterly) stood at $20.7 million in 2020, then crashed by 61.00% to $8.1 million in 2021, then slumped by 42.13% to $6.2 million in 2022.
  • Its last three reported values are $6.2 million in Q1 2022, $8.1 million for Q4 2021, and $8.9 million during Q3 2021.